Biogenera
The company develops a new generation of anti-gene oligonucleotide drugs based on Peptide Nucleic Acids (Ag-PNA) to treat incurable diseases. Its proprietary MyGenera platform identifies molecules that selectively silence altered genes responsible for aggressive pediatric tumors and rare diseases. The lead candidate, BGA002, specifically targets the MYCN gene for the treatment of neuroblastoma and rhabdomyosarcoma.
Visit websiteOzzano dell’Emilia, Italy
Biotechnology
Pharmaceuticals
Precision Medicine
Oncology
Funding summary
- Total raised
- €305K
- Funding rounds
- 1
Investors in Biogenera
Investors on record for Biogenera. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Biogenera?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors